Equivalency challenge: Evaluation of lipodox® as the generic equivalent for doxil® in a human ovarian cancer orthotropic mouse model

abstract

BACKGROUND:

The objective of this study was to evaluate the in vivo growth inhibition activity and tumor distribution of Doxil® compared to Lipodox® as its generic (GLD) in human ovarian cancer orthotopic mouse model.

CONCLUSION:

Significant differences in preclinical efficacy were observed between Doxil® and GLD. These may be due significant pharmacodynamic effects of drug distribution and decrease uptake of GLD in tumor tissue A prospective clinical comparison of these two products is warranted to determine equivalency.